ATARA BIOTHERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$5.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$122.00K.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$11.19M, a 221.01% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $9.25M.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$44.20M.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$16.69M.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$811.00K.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$67.10M.
- ATARA BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$14.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.26M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$122.00K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$16.69M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | -$19.43M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$8.27M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$11.19M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$811.00K 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $20.61M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $5.47M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $9.25M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$67.10M 10-K · filed 2025-03-07 | |||
| 2023-09-30 | -$28.15M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$47.04M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$44.20M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$14.39M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$41.02M 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | -$35.44M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$4.46M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$94.32M 10-K · filed 2023-02-08 | |||
| 2021-09-30 | -$87.19M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$76.55M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$49.31M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $126.09M 10-K · filed 2023-02-08 | |||
| 2020-09-30 | -$11.70M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $194.00K 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$4.11M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $13.62M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $33.73M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$1.54M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | -$4.53M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | -$18.52M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$13.20M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $23.98M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $11.27M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $32.45M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $13.72M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $17.47M 10-Q · filed 2018-08-01 | |||
| 2017-03-31 | $15.66M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $24.22M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |